

phenotype prediction from genotype (version 3.4)

I. General information

Patient:	Study Id:
Birth date:	Viral load:
Sample received:	Sample collected:
Sample ID: 50	Predicted subtype: B (100%)
Sample type:	Report date: October 7, 2018
Physician:	Reported by:

II. Substitutions (relative to the reference strain HXB2)

Protease:	V3I, T4A/T, L10F, I15I/V, K20K/T, E35D, S37N, M46I, I54V, L63P, I64V, A71V, I72L, G73T, V77I/V, I84V, I85V, L90M
Reverse transcriptase:	

III. Phenotype prediction

Drug	Resistance Factor RF (*)	z-score	Scored Positions (**)
ZDV	0	0	
ddI	0	0	
d4T	0	0	
3TC	0	0	
ABC	0	0	
TDF	0	0	
NVP	0	0	
EFV	0	0	
ETR (***)	Susceptible		
RPV (***)	Susceptible		
SQV	323.763	16.661	48G <u>84V</u> <u>11V</u> 74T 88N <u>90M</u> <u>53F</u> 95C 26T 1P <u>73T</u> 80T <u>34E</u> <u>72L</u> <u>47I</u>
IDV	396.539	15.649	82V 88N <u>90M</u> <u>29D</u> 1P <u>84V</u> <u>21E</u> <u>65E</u> <u>46I</u> <u>73T</u> <u>11V</u> <u>72L</u> <u>30D</u> 78G 98N
NFV	477.456	13.96	88N 30D <u>90M</u> <u>84V</u> <u>82V</u> 97L 68G 36M <u>46I</u> <u>31T</u> 75V 74T <u>5L</u> 2Q 1P
APV	89.663	13.875	76L 50I <u>84V</u> <u>32V</u> <u>46I</u> <u>10F</u> <u>22A</u> <u>63P</u> 1P 47I 13I 82V <u>90M</u> <u>97L</u> 45K
LPV	153.621	14.7	82V 50I <u>46I</u> <u>54V</u> <u>84V</u> 76L 22A <u>10F</u> <u>7Q</u> <u>63P</u> 24L 25D 47I 92Q 2Q
TPV	11.279	5.228	69H <u>46I</u> <u>48G</u> <u>84V</u> <u>33L</u> <u>90M</u> <u>47I</u> 91T <u>71V</u> <u>15V</u> 82V 74T 88N 58Q 19L
DRV	14.212	6.944	47I <u>84V</u> <u>33L</u> 76L 74T 43K 36M <u>65E</u> <u>10F</u> 48G <u>93I</u> <u>85V</u> <u>15I</u> <u>7Q</u> 8R
ATV	290.614	16.91	48G <u>84V</u> <u>82V</u> <u>90M</u> <u>73T</u> <u>72L</u> <u>88N</u> <u>7Q</u> 36M 24L 76L 45K 32V <u>20T</u> <u>46I</u>


(*) based on LIBSVM, Copyright (c) 2000, Chih-Chung Chang and Chih-Jen Lin

(**) Positions are ordered according to their impact on the phenotype prediction. Differences with respect to HXB2 are underlined. Positions shown in red and in green contribute to an increase or decrease in resistance, respectively. At most 15 positions are shown for each drug.

(***) Resistance predictions and scored mutations for ETR and RPV were performed with rules-based drug-resistance interpretation models by HIV-GRADE (<http://www.hiv-grade.de>)

IV. Interpretation

Patient:	Birth date:	Sampling date:
Current therapy:		Viral load:



■ susceptible ■ intermediate ■ resistant

(*)number of standard deviations above mean of drug naive patients. Negative z-scores may indicate hypersusceptibility.

NRTIs/NtRTI:

NNRTIs:

PIs:

Previous genotypes:

date

signature